iShares U.S. Pharmaceutical ETF (NY:IHE)

80.28 +0.03 (+0.04%)

Official Closing Price Updated: 8:00 PM EST, Nov 14, 2025 Add to My Watchlist

Price and Volume

Volume	39,763
Open	79.84
Bid (Size)	79.72 (3,100)
Ask (Size)	80.91 (3,100)
Prev. Close	80.25
Today's Range	79.82 - 80.96
52wk Range	58.97 - 81.06
Shares Outstanding	82,000
Dividend Yield	1.55%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Eli Lilly Supremacy: How One Stock Is Dictating Performance Across Pharma ETFs ↗

November 15, 2025

A look into how Eli Lilly's growth and large weightings are influencing major pharma ETFs, leaving investors more exposed to one stock than they realize.

Via Benzinga

Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily' ↗

November 12, 2025

Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."

Via Benzinga

Performance

YTD	+22.3%	+22.3%
1 Month	+8.1%	+8.1%
3 Month	+15.5%	+15.5%
6 Month	+23.4%	+23.4%
1 Year	+20.5%	+20.5%

More News

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗

October 30, 2025

Via Benzinga

White House Clarifies Recent Pharmaceutical Tariffs Exempt Countries with Trade Agreements: Report ↗

September 26, 2025

Via Stocktwits

Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗

September 29, 2025

Via Benzinga

Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms ↗

September 29, 2025

Via Benzinga

Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing ↗

September 08, 2025

Via Benzinga

Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More' ↗

August 01, 2025

Via Benzinga

Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption' ↗

July 28, 2025

Via Benzinga

Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills ↗

July 26, 2025

Via Benzinga

Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains' ↗

July 16, 2025

Via Benzinga

FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report ↗

July 11, 2025

Via Stocktwits

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies ↗

July 11, 2025

Via Benzinga

Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare' ↗

June 20, 2025

Via Benzinga

FDA Aims To Reduce Drug Application Review Time With New Voucher Program ↗

June 17, 2025

Via Stocktwits

Robert Kennedy Jr Axes Entire CDC Vaccine Panel To 'Restore Public Trust' — Pfizer, Moderna, Other Biotech Stocks Drop In After-Hours Trading ↗

June 10, 2025

Via Benzinga

Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion ↗

May 19, 2025

Via Benzinga

Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency' ↗

May 11, 2025

Via Benzinga

Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks ↗

May 08, 2025

Via Benzinga

Sandoz CEO Richard Saynor Slams Proposal For Europe-Wide List Price For New Medicines, Says Report ↗

April 28, 2025

Via Stocktwits

Trump Administration Considers Lowering US Drug Prices To International Levels: Report ↗

April 23, 2025

Via Benzinga

ETF Shake-Up: UNH's Meltdown Meets LLY's Moonshot ↗

April 18, 2025

Via Benzinga

Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies ↗

April 11, 2025

Via Benzinga

Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On? ↗

April 03, 2025

Via Benzinga

Trade War Redux: These ETFs Due For Bumpy Ride Thanks To Trump Tariffs On Auto, Pharma, Chip Imports ↗

February 19, 2025

Via Benzinga

Frequently Asked Questions

Is iShares U.S. Pharmaceutical ETF publicly traded?

Yes, iShares U.S. Pharmaceutical ETF is publicly traded.

What exchange does iShares U.S. Pharmaceutical ETF trade on?

iShares U.S. Pharmaceutical ETF trades on the New York Stock Exchange

What is the ticker symbol for iShares U.S. Pharmaceutical ETF?

The ticker symbol for iShares U.S. Pharmaceutical ETF is IHE on the New York Stock Exchange

What is the current price of iShares U.S. Pharmaceutical ETF?

The current price of iShares U.S. Pharmaceutical ETF is 80.28

When was iShares U.S. Pharmaceutical ETF last traded?

The last trade of iShares U.S. Pharmaceutical ETF was at 11/14/25 08:00 PM ET

What is the market capitalization of iShares U.S. Pharmaceutical ETF?

The market capitalization of iShares U.S. Pharmaceutical ETF is 6.58M

How many shares of iShares U.S. Pharmaceutical ETF are outstanding?

iShares U.S. Pharmaceutical ETF has 7M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.